Bayer's April Crucible: Legal Fate and Financial Fortitude Collide

Bayer's pivotal week includes a shareholder meeting and a U.S. Supreme Court hearing on glyphosate lawsuits, with billions in legal cash outflows looming.

For Bayer, the final week of April represents a convergence of pressures that could define its trajectory for years. The chemical and pharmaceutical giant faces a critical legal hearing in the United States just days after a pivotal shareholder meeting, all while managing a significant cash outflow.

The immediate financial calendar is packed. The company’s virtual Annual General Meeting on April 24th will see shareholders vote on a proposed dividend of 0.11 euros per share for the 2025 fiscal year, unchanged from the previous year. The ex-dividend date is set for April 27th, with payment following on April 29th. The meeting will also formalize a shift in supervisory board personnel, with Marcel Smits and OMV CEO Alfred Stern poised to replace Paul Achleitner and Colleen Goggins. Market observers interpret these appointments as reinforcing a sharper operational focus under CEO Bill Anderson.

Merely three days later, on April 27th, the oral arguments begin before the U.S. Supreme Court in the long-running glyphosate litigation. This hearing is a potential watershed. Bayer’s core legal argument rests on the claim that the federal FIFRA law, which sets nationwide standards for pesticide warnings, should preempt state-level cancer warning requirements. A favorable ruling could strip the legal foundation from thousands of pending lawsuits.

The financial stakes of the litigation are immense. Bayer has provisions for legal disputes totaling 11.8 billion euros. The company anticipates litigation-related cash outflows of approximately 5 billion euros in 2026 alone, a burden expected to push its free cash flow deeply negative, to between minus 1.5 and minus 2.5 billion euros. This pressure is projected to drive net financial debt up to 32-33 billion euros by year-end, from 29.8 billion euros previously.

Despite these substantial legal headwinds, Bayer’s management has reaffirmed its full-year EBITDA forecast of 9.6 to 10.1 billion euros. Operational leaders have also indicated that announced U.S. pharmaceutical tariffs are already factored into their planning, noting that the EU-US trade agreement caps duties on most European medicines at 15 percent.

Growth prospects provide a crucial counterbalance. The oncology drug Nubeqa, a key pharmaceutical asset, generated sales of nearly 2.4 billion euros in 2025. Furthermore, the anticoagulant Asundexian recently received Fast-Track designation from the FDA, a status that can accelerate its U.S. regulatory review. The company aims for its pharmaceuticals division to return to mid-single-digit growth from 2027 onward, targeting an operational margin approaching 30 percent by 2030.

Bayer’s share price, currently trading around 40 euros, sits just below its 50-day moving average of 41.51 euros. The stock has more than doubled from its low near 20 euros in April 2025 but remains roughly 18 percent below its 52-week high of 49.17 euros. The 40-euro level is viewed as a key psychological support. A potential, albeit indirect, boost could come from reports that domestic glyphosate production has been classified as a national security priority in the U.S., potentially strengthening Bayer’s hand with American regulators.

The durability of the stock’s recent stabilization will face a fresh test in May when first-quarter results are published. That report will offer the first public commentary from management following the Supreme Court hearings, providing investors with a clearer view of the path ahead.